ANRO
Income statement / Annual
Last year (2023), Alto Neuroscience, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Alto Neuroscience, Inc.'s net income was -$36.31 M.
See Alto Neuroscience, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
| Operating Revenue |
$0.00 |
$0.00 |
$210,000.00 |
| Cost of Revenue |
$373,000.00
|
$342,000.00
|
$145,000.00
|
| Gross Profit |
-$373,000.00
|
-$342,000.00
|
$65,000.00
|
| Gross Profit Ratio |
0
|
0
|
0.31
|
| Research and Development Expenses |
$30.29 M
|
$23.69 M
|
$8.37 M
|
| General & Administrative Expenses |
$7.52 M
|
$5.50 M
|
$3.90 M
|
| Selling & Marketing Expenses |
$0.00
|
-$342,000.00
|
-$145,000.00
|
| Selling, General & Administrative Expenses |
$7.52 M
|
$5.16 M
|
$3.75 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$37.81 M
|
$28.85 M
|
$12.12 M
|
| Cost And Expenses |
$37.81 M
|
$29.19 M
|
$12.27 M
|
| Interest Income |
$2.35 M
|
$114,000.00
|
$2,000.00
|
| Interest Expense |
$1.37 M
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$373,000.00
|
$342,000.00
|
$145,000.00
|
| EBITDA |
-$34.56 M |
-$27.37 M |
-$9.04 M |
| EBITDA Ratio |
0
|
0
|
-56.72
|
| Operating Income Ratio |
0
|
0
|
-57.41
|
| Total Other Income/Expenses Net |
$1.50 M
|
$1.48 M
|
$2.87 M
|
| Income Before Tax |
-$36.31 M
|
-$27.71 M
|
-$9.19 M
|
| Income Before Tax Ratio |
0
|
0
|
-43.75
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$36.31 M
|
-$27.71 M
|
-$9.19 M
|
| Net Income Ratio |
0
|
0
|
-43.75
|
| EPS |
-1.35 |
-1.08 |
-0.36 |
| EPS Diluted |
-1.35 |
-1.08 |
-0.36 |
| Weighted Average Shares Out |
$26.88 M
|
$25.57 M
|
$25.57 M
|
| Weighted Average Shares Out Diluted |
$26.88 M
|
$25.57 M
|
$25.57 M
|
| Link |
|
|
|
